Artelo Biosciences, Inc. (ARTL)
3.11
-0.15
(-4.60%)
USD |
NASDAQ |
Oct 12, 16:00
3.10
-0.01
(-0.32%)
After-Hours: 20:00
Artelo Biosciences Enterprise Value : 8.877M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 8.877M |
| October 09, 2026 | 9.505M |
| October 08, 2026 | 9.966M |
| October 07, 2026 | 10.13M |
| October 06, 2026 | 10.34M |
| October 05, 2026 | 10.55M |
| October 02, 2026 | 11.26M |
| October 01, 2026 | 11.89M |
| September 30, 2026 | 12.77M |
| September 29, 2026 | 12.90M |
| September 28, 2026 | 13.86M |
| September 25, 2026 | 14.87M |
| September 24, 2026 | 17.50M |
| September 23, 2026 | 26.47M |
| September 22, 2026 | 13.23M |
| September 21, 2026 | 13.02M |
| September 18, 2026 | 12.35M |
| September 17, 2026 | 12.48M |
| September 16, 2026 | 11.56M |
| September 15, 2026 | 18.22M |
| September 14, 2026 | 16.25M |
| September 11, 2026 | 18.59M |
| September 10, 2026 | 19.43M |
| September 09, 2026 | 20.90M |
| September 08, 2026 | 21.78M |
| Date | Value |
|---|---|
| September 04, 2026 | 21.15M |
| September 03, 2026 | 21.90M |
| September 02, 2026 | 23.16M |
| September 01, 2026 | 21.63M |
| August 31, 2026 | 22.49M |
| August 28, 2026 | 20.83M |
| August 27, 2026 | 20.77M |
| August 26, 2026 | 22.64M |
| August 25, 2026 | 22.89M |
| August 24, 2026 | 21.82M |
| August 21, 2026 | 21.94M |
| August 20, 2026 | 22.71M |
| August 19, 2026 | 22.99M |
| August 18, 2026 | 23.36M |
| August 17, 2026 | 23.03M |
| August 14, 2026 | 25.64M |
| August 13, 2026 | 24.45M |
| August 12, 2026 | 23.48M |
| August 11, 2026 | 23.92M |
| August 10, 2026 | 22.43M |
| August 07, 2026 | 23.03M |
| August 06, 2026 | 24.21M |
| August 05, 2026 | 24.17M |
| August 04, 2026 | 24.69M |
| August 03, 2026 | 23.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.925B |
| Corcept Therapeutics, Inc. | 12.78B |
| Veru, Inc. | 17.90M |
| Johnson & Johnson | 663.40B |
| Eli Lilly & Co. | 1.159T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.427M |
| Total Expenses (Quarterly) | 2.427M |
| EPS Diluted (Quarterly) | -0.8949 |
| Earnings Yield | -739.0% |
| Normalized Earnings Yield | -697.99 |